The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ACELYRIN INC COM 00445A100   11,952,127 3,806,410 SH   SOLE   3,806,410 0 0
ALUMIS INC COM 022307102   21,908,948 2,787,398 SH   SOLE   2,787,398 0 0
ALX ONCOLOGY HLDGS INC COM 00166B105   16,198,875 9,699,925 SH   SOLE   9,699,925 0 0
ARTIVA BIOTHERAPEUTICS INC COM 04317A107   15,321,308 1,519,971 SH   SOLE   1,519,971 0 0
HARMONY BIOSCIENCES HLDGS IN COM 413197104   18,553,666 539,194 SH   SOLE   539,194 0 0
LYELL IMMUNOPHARMA INC COM 55083R104   4,545,402 7,102,190 SH   SOLE   7,102,190 0 0
PHARVARIS N V COM N69605108   82,225,958 4,289,304 SH   SOLE   4,289,304 0 0